Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget | Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression

News

January 5, 2023
PRESS RELEASE: On December 20, 2022, Oncotarget published a new research paper, entitled, “Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression.” continue reading »

Novel Antibody Drug Conjugate Improves Murine Acute Myeloid Leukemia

Oncotarget

January 4, 2023
Researchers from Astellas Pharma Inc. investigated the efficacy of a novel antibody drug conjugate combined with venetoclax and azacitidine in a mouse model of acute myeloid leukemia. continue reading »

Oncotarget | Serum microRNAs as new criteria for referral to early palliative care services in treatment-naïve advanced cancer patients

News

December 29, 2022
PRESS RELEASE: On December 17, 2022, a new research paper was published in Oncotarget, entitled, “Serum microRNAs as new criteria for referral to early palliative care services in treatment-naïve advanced cancer patients.” continue reading »

Oncotarget | The role of pyrethroid derivatives in autophagy and apoptosis crosstalk signaling and potential risk for malignancies

News

December 28, 2022
PRESS RELEASE: On December 17, 2022, a new research paper was published in Oncotarget, entitled, “The role of pyrethroid derivatives in autophagy and apoptosis crosstalk signaling and potential risk for malignancies.” continue reading »

Oncotarget | Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients

Oncotarget

December 22, 2022
PRESS RELEASE: A new research paper was published in Oncotarget, entitled, “Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.” continue reading »